Hallgeir Rui
Affiliations: | Uniformed Services University of the Health Sciences, Bethesda, MD |
Area:
Molecular Biology, Oncology, Cell BiologyGoogle:
"Hallgeir Rui"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Clevenger CV, Rui H. (2022) Breast cancer and prolactin - new mechanisms and models. Endocrinology |
| Geethadevi A, Nair A, Parashar D, et al. (2021) Oncostatin M Receptor-targeted antibodies suppress STAT3 signaling and inhibit ovarian cancer growth. Cancer Research |
| Rädler PD, Wehde BL, Triplett AA, et al. (2021) Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells. Nature Communications. 12: 3742 |
| Cho C, Mukherjee R, Peck AR, et al. (2020) Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis. Oncogene |
| Rau A, Manansala R, Flister MJ, et al. (2020) Individualized multi-omic pathway deviation scores using multiple factor analysis. Biostatistics (Oxford, England) |
| Odnokoz O, Yu P, Peck AR, et al. (2020) Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. Cancer Biology & Therapy. 1-8 |
| Morita Y, Leslie M, Kameyama H, et al. (2020) Functional Blockade of E-Selectin in Tumor-Associated Vessels Enhances Anti-Tumor Effect of Doxorubicin in Breast Cancer. Cancers. 12 |
| Pestell RG, Cristofanilli M, Rui H, et al. (2020) Abstract PD4-04: Leronlimab, a humanized monoclonal antibody to CCR5, restrains breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapies Cancer Research. 80 |
| Chaudhary LN, Jorns J, Gonyo M, et al. (2020) Abstract P6-04-23: HER2 up-regulation with neoadjuvant endocrine therapy in patients with hormone receptor-positive, HER2-negative breast cancer Cancer Research. 80 |
| Liu J, Fantacone-Campbell JL, Kovatich AJ, et al. (2020) Abstract P2-18-03: Breast cancer treatment and association with clinicopathologic features in TCGA Cancer Research |